Trial Profile
A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Feb 2019 Status changed from active, no longer recruiting to completed.
- 16 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.